{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:30Z","timestamp":1793120070631,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020660","name":"The University of Hong Kong State Key Laboratory of Liver Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jhep.2024.03.022","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:19:32Z","timestamp":1711451972000},"page":"218-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0451-1473","authenticated-orcid":false,"given":"Ryan Hin-Man","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-7539","authenticated-orcid":false,"given":"Rex Wan-Hin","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-8808","authenticated-orcid":false,"given":"Kevin Sze-Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-5005","authenticated-orcid":false,"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-8902","authenticated-orcid":false,"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.03.022_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.03.022_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3350\/cmh.2022.0399","article-title":"Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective","volume":"29","author":"Hui","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib4","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV\/HDV treatment endpoints conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.022_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.03.022_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728214.2022.2074977","article-title":"Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials","volume":"27","author":"Hui","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.jhep.2024.03.022_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17474124.2023.2196405","article-title":"Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy","volume":"17","author":"Hui","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib8","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2024.03.022_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.022_bib10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jmv.25015","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio associated with prognosis in HBV-infected patients","volume":"90","author":"Gong","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2024.03.022_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12072-012-9373-4","article-title":"Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.03.022_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043087","article-title":"High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"PloS one"},{"key":"10.1016\/j.jhep.2024.03.022_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.03.022_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.03.022_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.03.022_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.03.022_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.03.022_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.03.022_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study","volume":"215","author":"Cao","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2024.03.022_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.022_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jvh.12766","article-title":"Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study","volume":"25","author":"Hui","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.03.022_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2024.03.022_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2010.03.020","article-title":"Hepatitis B virus genotyping: current methods and clinical implications","volume":"14","author":"Guirgis","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2024.03.022_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhep.2004.03.004","article-title":"Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong","volume":"41","author":"Yuen","year":"2004","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2026.05.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000}},{"DOI":"10.1016\/j.jhep.2026.05.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:58:37Z","timestamp":1773457117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0168827824002046"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}